49
Participants
Start Date
February 28, 2005
Primary Completion Date
March 31, 2009
Study Completion Date
March 31, 2009
Pemetrexed
Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle
Folic Acid
All participants received oral Folic Acid 350-100ug once per day for 7 days preceding the first pemetrexed dose and continuing throughout the study and and for 21 days after the last dose of pemetrexed.
Vitamin B12
All patients received vitamin B12 1000ug intramuscular injection the week preceding the first pemetrexed dose and received additional 1000ug intramuscular injections every three cycles thereafter on the same day of pemetrexed administration.
Consultants in Medical Oncology & Hematology, Drexel Hill
Pennsylvania Oncology-Hematology Associates, Philadelphia
Indiana University Cancer Center, Indianapolis
Quality Cancer Center (MCGOP), Indianapolis
Community Regional Cancer Center, Indianapolis
Elkhart Clinic, Elkhart
Northern Indiana Cancer Research Consortium, South Bend
Fort Wayne Oncology & Hematology, Inc, Fort Wayne
Medical Consultants, P.C., Muncie
AP&S Clinic, Terre Haute
Arnett Cancer Care, Lafayette
Center for Hematology/Oncology of S. Michigan, Jackson
Medical & Surgical Specialists, LLC, Galesburg
Methodist Cancer Center, Omaha
Hematology Oncology Associates S.J., P.A., Mount Holly
Eli Lilly and Company
INDUSTRY
Walther Cancer Institute
OTHER
Christopher Sweeney, MBBS
OTHER